ONCOLOGY DRUG PIPELINE ANALYSIS MARKET ANALYSIS

Leading Companies

Key players are focused on mergers and collaborations to expand their share in the oncology drug pipeline market. For instance, in February 2018, Merck & Co., Inc. acquired Viralytics Ltd—an Australia-based oncolytic immunotherapies manufacturer— for US$ 394 million, to strengthen Merck & Co.’s presence in the immuno-oncology market.

Furthermore, in September 2018, Daiichi Sankyo Company, Limited, entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., to evaluate the combination of Daiichi Sankyo’s investigational Human Epidermal Growth Factor 2 (HER2) targeting antibody drug conjugate DS-8201 and Pembrolizumab. This combinational drug is intended to be used for metastatic breast and non-small cell lung cancers and is under clinical phase II development.

Key players operating in the global oncology pipeline drugs market include, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, Pfizer Inc., AbbVie Inc., Celgene Corporation, Novartis AG, Merck & Co., Inc., Sanofi, Eli Lilly & Co., GlaxoSmithKline, and Amgen Inc.